Following the news that Donald Trump is the winner of the 2024 US Presidential Election, Morningstar Equity analyst Julie Utterback has published a new note about the impact of this on the managed-care industry. 7 November 2024
Vertex Pharmaceuticals today announced that the European Commission has granted approval for Alyftrek (deutivacaftor/tezacaftor/vanzacaftor) for the treatment of people with cystic fibrosis (CF) ages six years and older who have at least one non-class I mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. 1 July 2025
Marking a new step forward in its international growth, Spanish privately-held pharma company Esteve has entered into an agreement with Sanofi to acquire French pharma major Sanofi’s Caprelsa (vandetanib) rights in more than 50 countries, a treatment that is used in adults and children above five years of age to treat aggressive and symptomatic medullary thyroid cancer. 1 July 2025
The US Food and Drug Administration (FDA) is revising the labeling of all extended-release stimulants indicated to treat attention-deficit/hyperactivity disorder (ADHD)—including certain formulations of amphetamine and methylphenidate—to warn of the risk of weight loss and other adverse reactions in patients younger than six years. 1 July 2025
Denmark-based Vesper Bio, a biotech developing an oral therapy for frontotemporal dementia, has announced the appointment of Jacob Falck Hansen as chief executive. 1 July 2025
Clinical-stage oncology company Revolution Medicines and fellow USA-based Summit Therapeutics have entered into a clinical collaboration in multiple solid tumor settings. 1 July 2025
Shares in US biotech INmune Bio slumped by around 60% following news that its Phase II Alzheimer’s study failed to hit its primary endpoint. However, the company is now pointing to encouraging signs in a subset of patients, which it says could guide future development of its candidate, XPro (pegipanermin). 1 July 2025
Chinese biopharma Hutchmed today announced that the New Drug Application (NDA) for the combination of Orpathys (savolitinib) and Tagrisso (osimertinib) has been granted approval by the China National Medical Products Administration (NMPA). 30 June 2025
US pharma major AbbVie is to buy Capstan Therapeutics, a San Diego-based biotech advancing in vivo engineering of cells through RNA delivery using tLNPs, for up to $2.1 billion in cash. 30 June 2025
Johnson & Johnson has announced the submission of an extension of indication application to the European Medicines Agency (EMA) seeking approval of Akeega (niraparib/abiraterone acetate) with prednisone or prednisolone for the treatment of adults with metastatic hormone-sensitive prostate cancer (mHSPC) and homologous recombination repair (HRR) gene alterations. 3 July 2025
Theratechnologies, a Canada-based biopharma, is to be acquired by CB Biotechnology, an affiliate of Future Pak, a privately-held contract manufacturer, packager and distributor of pharmaceutical and nutraceutical products. 4 July 2025